ESMO 2024 | Estrogen patches as a safer androgen suppression alternative in prostate cancer

Name: Estrogen patches as a safer androgen suppression alternative in prostate cancer
Uploaded: 2024-09-16T00:00:00Z
Duration: 2 min

Duncan Gilbert • 16 Sep 2024

ESMO 2024

Genitourinary Cancer Prostate Cancer

Duncan Gilbert, MA, MRCP, FRCR, PhD, University College London, London, UK, discusses the role of androgen suppression in prostate cancer treatment, traditionally achieved with LH-RH analogues, which lower testosterone but also reduce estrogen, leading to side effects like hot flushes, fatigue, and bone health deterioration. A safer alternative is using estrogen patches, which suppress testosterone without reducing estrogen, mitigating these side effects. Unlike oral estrogen, which increases cardiovascular risks, patches bypass liver metabolism and have shown no increased cardiovascular risk. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.